Close Menu

NEW YORK (360Dx) – Last summer was a notable one for the clinical mass spectrometry market as three major vendors — Sciex, Thermo Fisher Scientific, and Roche — announced plans to release instruments specifically targeting the clinical market.

Perhaps most significantly, the latter two firms said they intended to develop fully automated instruments analogous to current clinical analyzers, which could drive mass spec's move into the clinic by fitting it more seamlessly into existing workflows and eliminating the need for expert users.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.